title: Recurrence after surgical resection of gastrinoma:  who, when, where and why?
abstract: BACKGROUND
  Surgery prolongs survival in patients with gastrinomas, but postoperative recurrences are frequent and controversies still exist about the optimal surgical procedures.
  
  
  OBJECTIVE
  The aim of this study is to analyze biological and morphological recurrences and to search for risk factors.
  
  
  METHODS
  Between 1990 and 2008, 22 patients (five with multiple endocrine neoplasia type 1) who underwent curative resection for gastrinoma were evaluated every 6 months for biological and morphological recurrences. All patients were disease-free postresection.
  
  
  RESULTS
  The median postoperative follow-up was 37 months (range, 7-204 months). A biological recurrence was observed in 59% of cases, after a median time of 16.5 months (range, 7-90 months). A morphological recurrence was reported in 32% of cases, in the liver (86%) or lymph nodes (43%), after a median time of 21 months (range, 8-91 months). The median delay between biological and morphological recurrence was 3 months (range, 0-69 months). At recurrence, all patients were offered a second treatment (surgical resection in 71% of cases). One and 5 year overall survival were 100 and 76%, respectively. One and 5 year biological disease-free survival (DFS) were 76 and 27%, respectively. One and 5 year morphological DFS were 90 and 62%, respectively. Tumor size of at least 20 mm (P=0.008) and pancreatic location (P=0.04) of the primary tumor had significant effect on morphological DFS. Overall survival was significantly lower in patients with primary tumor of at least 20 mm (P=0.01).
  
  
  CONCLUSIONS
  (a) Recurrence occurs in nearly two out of three patients operated upon for gastrinoma, most often detected through biological tests; (b) lymph nodes and liver are the most frequent sites of relapse and patients benefit from second treatment; (c) risk factors for recurrences are as follows: size of at least 20 mm; and the pancreatic location of the primary tumor.
authors.affiliation: Department of Gastroenterology and Pancreatology, Beaujon University Hospital, AP-HP, Clichy, France. frederique.maire@bjn.aphp.fr
authors.forename: Frédérique
authors.initials: F
authors.lastname: Maire
authors.forename: Alain
authors.initials: A
authors.lastname: Sauvanet
authors.forename: Anne
authors.initials: A
authors.lastname: Couvelard
authors.forename: Vinciane
authors.initials: V
authors.lastname: Rebours
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Vullierme
authors.forename: Rachida
authors.initials: R
authors.lastname: Lebtahi
authors.forename: Olivia
authors.initials: O
authors.lastname: Hentic
authors.forename: Jacques
authors.initials: J
authors.lastname: Belghiti
authors.forename: Pascal
authors.initials: P
authors.lastname: Hammel
authors.forename: Philippe
authors.initials: P
authors.lastname: Lévy
authors.forename: Philippe
authors.initials: P
authors.lastname: Ruszniewski
mesh_terms: D000328:Adult; D000368:Aged; D004379:Duodenal Neoplasms / Q000473:pathology / Q000601:surgery*; D004812:Epidemiologic Methods; D005260:Female; D015408:Gastrinoma / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000601:surgery; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000601:surgery; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D016896:Treatment Outcome